Predictmedix Inc (CSE:PMED, OTCQB:PMEDF) has announced the results of its latest study using the company's proprietary AI technology to detect alcohol and cannabis impairment, along with an upcoming trial in a North American clinical setting.
The Toronto-based company revealed that in a supervised environment with 128 participants, the company's AI technology demonstrated a 79%-87% efficacy in the identification of cannabis impairment, and 76%-92% efficacy in the identification of alcohol impairment depending on the amount of cannabis or alcohol consumed by the subject.
Predictmedix's proprietary impairment detection technology detects cannabis and alcohol impairment using AI algorithms based on a multiparametric approach to identify unique features from multispectral imaging and voice analysis.
The company filed a US patent for the technology in 2020. The technology does not require biological fluids and is contactless, quick, easy to use, cost-effective, and provides immediate results.
READ: Predictmedix announces inaugural placement of its Safe Entry Station at Ontario-based health and wellness retreat
"We are incredibly pleased with the ability of our technology in detecting both cannabis and alcohol impairment, which presents a global opportunity in industry-wide workplace settings and law enforcement agencies," said Rahul Kushwah, interim chief executive officer of Predictmedix.
He added: "While the results as they stand now are impressive, it is important to note that, as an AI-based solution, the technology is inherently self-learning. Given this aspect of the technology, its efficacy should continue to improve over time as more data is obtained and processed, causing the system to become ‘smarter'."
Building on the datasets and insights from this and other previous research, the company said that it is also commencing an additional clinical study in February 2022 with researchers and doctors at a North American hospital.
If the study shows similar results, the hospital study will provide third-party independent validation of the company's impairment detection solution ahead of commercial launch.
The data collected can be used by Predictmedix to further fine-tune the AI algorithms, the company said. The results of the independently validated study will be published in a peer-reviewed medical journal.
"Organizations are extremely concerned about workplace impairment and resulting injuries and accidents due to alcohol and drug use. We know from many studies that blood and oral fluid THC concentrations are relatively poor or inconsistent indicators of cannabis-induced impairment, so it is essential for employers to have an impairment detection solution that is accurate, contactless, quick, easy to use, cost-effective, and provides immediate results for both cannabis and alcohol presence" said Sheldon Kales, chairman of the board of directors, in a statement.
Contact Ritika at ritika@proactiveinvestors.com